{"id":"NCT02226003","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-23","primaryCompletion":"2016-02-23","completion":"2016-02-23","firstPosted":"2014-08-26","resultsPosted":"2017-04-07","lastUpdate":"2018-09-13"},"enrollment":291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Ertugliflozin","otherNames":[]},{"type":"DRUG","name":"Sitagliptin","otherNames":[]},{"type":"DRUG","name":"Placebo to Ertugliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo to Sitagliptin","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":[]}],"arms":[{"label":"Ertugliflozin 5 mg and Sitagliptin 100 mg","type":"EXPERIMENTAL"},{"label":"Ertugliflozin 15 mg and Sitagliptin 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo to Ertugliflozin and Placebo to Sitagliptin","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in combination with sitagliptin in the treatment of participants with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise. The primary hypothesis of the study is that ertugliflozin plus sitagliptin is more effective in lowering of hemoglobin A1C (HbA1C) than placebo.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Ertugliflozin 5 mg + Sitagliptin 100 mg","deltaMin":-1.6,"sd":null},{"arm":"Ertugliflozin 15 mg + Sitagliptin 100 mg","deltaMin":-1.68,"sd":null},{"arm":"Placebo","deltaMin":-0.44,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"< 0.001"},{"comp":"OG001 vs OG002","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29313282","32700393","32648108","32372382","32324082","32324065","31797522"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":98},"commonTop":["Blood glucose increased","Urinary tract infection","Hyperglycaemia"]}}